Travere Therapeutics: Chief Legal Officer Buys 10,000 Shares Amid CEO‑Led Sell‑Off, Signaling “Buy the Dip” Strategy for Investors

Insider Activity at Travere Therapeutics: What the Latest Deal Signals

On February 17, 2026, Chief Legal Officer and General Counsel Elizabeth Reed purchased 10 000 shares of Travere Therapeutics at $19.08 per share, bringing her holdings to 115 211. This move comes shortly after a wave of sales by several senior executives, including the CEO, CFO, and CRO, who collectively sold roughly 300 000 shares between January 20 and February 4. The contrast between Reed’s buy and her recent pattern of selling—most notably the 7 175‑share sale on February 3 at $32.12—raises questions about her confidence in the company’s near‑term trajectory.

Implications for Investors Reed’s purchase at a price that is roughly 30 % below the current market level (27.87) and 35 % below the 12‑month low (12.91) suggests a contrarian stance. Her trades are often executed under Rule 10b‑5‑1(c) plans, indicating a disciplined, forward‑looking strategy rather than a reaction to insider information. The fact that she has consistently bought shares when the stock dips (e.g., 10 000 shares on January 20 at $19.08 and 25 110 shares on January 31 when the price was still below $27) points to a belief that Travere’s valuation is temporarily depressed. For investors, this could signal that the company’s fundamentals—particularly its pipeline of rare‑disease therapies—may soon generate positive cash flows that the market has yet to price in.

What It Means for Travere’s Future Travere’s latest quarterly results are pending, but the company’s 52‑week high of $42.13 and a 33.30 % year‑to‑date gain indicate a resilient upside potential. Reed’s recent acquisition, coupled with the broader insider buying trend (the CEO and CRO have also purchased shares in early February), suggests that management is positioning itself for a forthcoming catalyst, such as a regulatory approval or a strategic partnership. However, the negative earnings (P/E of –28.08) and the fact that the company has yet to turn profitable warn that any upside will likely be driven by pipeline milestones rather than immediate revenue growth.

Reed Elizabet’s Transaction Profile Over the past year, Reed has executed a mix of sales and purchases totaling 30 000 shares. Her most significant sell was 10 000 shares on January 20 at $27.34, coinciding with a broader sell‑off by senior executives. She has also sold option‑derived shares under 10b‑5‑1(c) plans at prices ranging from $27.01 to $28.50, demonstrating a willingness to lock in gains when the stock is above $27. Her purchase activity is concentrated around periods of market volatility, suggesting that she views Travere as a value play that is undervalued during downturns. The recent buy at $19.08—well below the current price—highlights her confidence that the company’s valuation is still below its intrinsic worth.

Takeaway for Market Participants Reed’s latest purchase, set against a backdrop of widespread insider selling, may be interpreted as a “buy the dip” signal for the company. While the stock’s negative earnings and the pending quarter’s results temper enthusiasm, the insider behavior indicates that those who know the company best believe in a near‑term upside. For investors, this could be an opportune moment to assess Travere’s pipeline and risk profile before the next earnings report, as the company’s valuation may accelerate if the pipeline delivers the expected milestones.